U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service

A U.K. health agency said the Alzheimer’s drugs Kisunla and Leqembi are not cost-effective, meaning they won’t be offered through the NHS.

Read the full article here

Related Articles